Q3 2020 Astellas Pharma Inc Earnings Call Transcript
I'm the CSO and CFO, Naoki Okamura. Thank you very much for participating in the conference call by Astellas on the third quarter financial results for fiscal year 2019. Today, the time is limited. So initially, I'd like to spend about 20 minutes to give you an overview of the financial results and explain the initiatives for sustainable growth and capital allocation. And then we will entertain your questions later.
Page 2 is a cautionary statement regarding forward-looking information, which was already read, so please turn to Page 4. First of all, this is an overview of the third quarter financial results based on year-on-year comparisons. Revenue and core operating profit declined, but excluding ForEx impact, revenue and profit increased. So our business progressed favorably as expected, due to the LOE of Tarceva, VESIcare in the United States and Europe and Tarceva in the United States and termination of Symbicort and KM bioproducts in Japan, sales declined substantially.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
